Home / Transcripts / Teva Pharmaceutical Industries Limited (TEVA) · November 3, 2026

Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Transcript

November 3, 2026

New York Stock Exchange US Health Care Pharmaceuticals earnings 70 min

Earnings Call Speaker Segments

Christopher Stevo executive
#1

Thank you, Elliot. Good morning and good afternoon to all of you. We appreciate you being with us on this call covering our third quarter earnings. Our materials went up on the website this morning, as they always do, so please take a look at them there. Before handing things over to Richard Francis, our CEO, I want to remind everybody that forward-looking statements will be made during this call. The company advises investors that any forward-looking statement carries risks and uncertainties and should not be taken as a guarantee of future performance. Because of a variety of factors, actual results could differ materially from those expressed or implied in the forward-looking statements. Those factors are set out in our earnings press release along with our most recent forms 10-Q and 10-K filed with the SEC. Any statements we make speak only as of today, and we assume no obligation to update those statements subsequently. That said, I will now take on the obligation of giving you our CEO, Richard Francis.

Richard Francis executive
#2

Thanks, Chris. Good morning, everyone, and good afternoon too. We appreciate all of you joining the call. With me today are Dr. Eric Hughes, who heads Global R&D and is our Chief Medical Officer, and Eli Kalif, our CFO. Let's move to the next slide. As I usually do, I'll start with the pivot to growth strategy and its four pillars. That strategy began in 2023, and in Q3 I'll take you through how we're doing against it. First, delivering on our growth engines. The innovative portfolio, as you can see, continues to perform well. AUSTEDO, AJOVY, and UZEDY each delivered strong Q3 results, and our innovative portfolio is up 33%. We are increasing our guidance for the entire year on all these products; how much these products matter is evident in our financial results, and you will also observe improved revenue, improved margins, and improved free cash flow. Moving to pillar two, step up innovation. So far this year we have had eight major milestone readouts, and we have also witnessed some substantial progress. The approval of UZEDY was a major event for Teva and for patients who suffer from schizophrenia. The pipeline is progressing nicely as well, and our anti-IL-15 candidate for celiac disease carries FDA fast-track designation. Going forward, we have four more potential submissions during the next five years. About the news we shared earlier this week: following a pre-specified interim futility analysis by an independent data monitoring committee, the phase II study of emrusolmin has been stopped. I want to note that no safety issues emerged. This result isn't the one I wanted, and I feel profound disappointment for the patients we aim to help and for the physicians who joined us on this journey—yet I'm especially proud of our teams and the work they devoted to this program. Whatever we've learned, we'll carry forward with still greater resolve. One more pipeline update that came before the earnings concerned BioXcel and the BXCL501 acquisition. We believe this asset will further reinforce our neuroscience franchise and our psychiatric portfolio. In our view, there is a substantial unmet medical need when it comes to treating agitation at home, and we think that in Teva's hands this could genuinely benefit patients facing that need. Turning now to the sustained generics powerhouse: as you'll see across the presentation, biosimilars are now becoming a meaningful growth driver for Teva and for our generics business. Fifteen products are already on the market, with another 16 in our pipeline, and there are further opportunities to build this out. You probably saw the press release earlier today about how we've deepened our partnership with Samsung through two anti-TNF-alpha biosimilars that carry FDA approval. Turning to the final pillar, capital allocation: after the latest S&P upgrade, Teva is now rated investment-grade by all three of the major agencies, a sign that our financial profile has stayed solid. We also refinanced $4.9 billion in senior notes over the past quarter, and we're glad to have that wrapped up. And on the subject of converting ADSs into ordinary shares on the New York Stock Exchange, we've opened the door for a broader set of investors to access Teva. I want to start with the thing I see as our biggest Q3 achievement: getting UZEDY approved and brought to market. That's a milestone for Teva, though what matters even more is that it marks progress in how people living with schizophrenia get treated. Let me be clear — patients come first. Schizophrenia is a terrible illness, and every relapse can hit patients hard, and their families too. UZEDY offers the efficacy of olanzapine that's already proven, in a subcutaneous injection taken once a month, which can help patients stay on their treatment and relapse less often. It's the first and only long-acting injectable that needs no loading dose, no oral supplementation, and no monitoring after the injection. So because of that, we think UZEDY could truly change things for individuals living with schizophrenia. And where's the real opportunity? The next slide shows it's a big one. In the U.S., 2.2 million people have a schizophrenia diagnosis; about 1.7 million of them are receiving treatment, and roughly 20% of prescriptions are written for oral olanzapine. It's common knowledge that olanzapine brings proven efficacy along with a well-characterized safety profile, which gives WELTRUZA a solid base to build on. On top of that, I believe we're all in agreement that our commercial team is strongly positioned for WELTRUZA to do well, leveraging the excellent progress made with UZEDY across the past three years. I'll go into that further in a bit. Taken together, these two offerings form a lineup built to tackle a wide range of unmet needs — UZEDY and WELTRUZA are highly differentiated yet work well alongside each other. They serve as the foundation for the two well-established molecules, risperidone and olanzapine. Because of this, we feel confident about achieving peak sales between $1.5 billion and $2 billion. Let's now move on to the financials. Q3 2026 captures Teva's shift into a biopharma company, and the numbers themselves make that clear, so I'll take you through it. Revenue was down 2%, while our gross margin climbed to 58.7%. That's a 345 basis point increase. EBITDA rose 7%, and non-GAAP EPS was 10% higher. I recall back in 2023, during my first quarter presenting as CEO, our gross margin stood at roughly 48%. That really illustrates how far we've come in moving this company from being purely a generics player to becoming a biopharma company; it isn't a single-quarter phenomenon. It mirrors the deliberate decisions we've taken to transform the business. In 2023, we set ourselves the objective of becoming a biopharma company, and these results show that this transformation is already in motion. What I'd highlight is that there is more progress to come. These figures include an IPR&D effect, and Eli Kalif will explain that in a moment. Let's move to the next slide. Total revenues came in at $4.4 billion. Innovative climbed 32% versus a year earlier, as I noted. AUSTEDO rose 21% worldwide, reaching $751 million. UZEDY gained 96%, hitting $85 million, while AJOVY jumped 61% to $269 million. Generics fell 16%, driven mostly by the weak contribution from generic REVLIMID revenue. Let me now give a little more detail. Turning to AUSTEDO. AUSTEDO hit its $2.5 billion goal a full year early. I'm genuinely, genuinely proud of this, and congratulations go to the team for pulling it off. U.S. revenues rose to $727 million, a 21% increase, and the underlying fundamentals stay solid. U.S. TRX was up 18%, and milligram dispense was up 23%. Given that solid momentum, we lifted our guidance by $75 million at the midpoint, which puts AUSTEDO in the $2.55 billion to $2.65 billion range. Nice work, team. I'd like to stress that AUSTEDO's opportunity remains strong. As you can see, market growth continues to hold up.

Richard Francis executive
#3

On the new-patient side, given that 85% of patients aren't treated, we believe there's a strong chance to grow this product beyond $2 billion at peak sales, which is what we've said before. Now on UZEDY: it's the LAI for schizophrenia growing faster than any other. Q3 revenue climbed 96%, reaching $85 million, and underlying demand is still robust—TRX and LAT each rose 62% versus a year ago. Thanks to outstanding commercial execution, the market itself is expanding: UZEDY has almost doubled its share of risperidone LAI from 5% to 10% and is taking about 83% of risperidone LAI. Just keep in mind, if you look back at 2025, Q3 and Q4, there were some one-off negative impacts, so factor that in as you plan ahead; that said, we raised our UZEDY outlook by $20 million at the midpoint, and the range is now $290 million-$310 million. It probably goes without saying, but I'll say it anyway, that this continued excellent execution gives us a solid foundation from which to launch WELTRUZA. Now on to AJOVY. AJOVY keeps extending its global leadership in migraine, keeps outperforming the injectable market, and leads in many markets where we have launched. Worldwide sales came in at $269 million, a 61% increase compared with the prior year, and we're seeing solid traction in numerous markets; U.S. sales climbed 89%, and outside the U.S. we continue to see healthy momentum driven by higher volumes and share gains. Given that strength, we lifted guidance by $85 million at the midpoint, taking it to a range of $930 million to $960 million. I want to emphasize that this isn't accidental. If you recall back when we began this effort in 2023, no one was discussing AJOVY, and we brought it back to life. I believe this says something larger about Teva. We act deliberately, and we follow through with real intensity. So for that reason, when we look past 2026, we can see a route toward peak sales exceeding $1 billion for AJOVY. Let me now turn to a few new products in our pipeline that I mentioned earlier. First, ecopipam. It's a first-in-class prospect for Tourette syndrome, pairing strong efficacy with good tolerability in a serious pediatric neurological condition where treatment choices are scarce. Each year, 100,000 pediatric patients are living with Tourette syndrome. Of those, 50,000 receive treatment, yet sadly just 20%-30% are still on therapy a year later. We want to change that and to help these patients and these children. Our next major milestone is securing regulatory approval, which we expect in Q1 2027. Turning now to the newest item in our innovative pipeline: the asset we picked up from BioXcel, BXCL501. It is intended to tackle a further obvious gap in care for individuals suffering acute agitation at home, broadening our neuroscience patient focus and potentially helping close to 7 million patients. Should regulators clear it, BXCL501 could be the first at-home treatment for acute agitation, which would contribute one more distinctive opportunity and substantial worth to our neuroscience portfolio. It further demonstrates disciplined capital allocation—spotting distinctive assets in which Teva can truly add value. Next week at our R&D day, my colleagues will go deeper on ecopipam and BXCL501; let's turn to the next slide. On the topic of growth—and the impressive growth in Q3—it's worth pointing out that our growth catalysts extend across a decade. As shown here, our pipeline is maturing, and Eric Hughes will cover that in more detail next week. Turning to 2030 and beyond, this particular slide gets pretty crowded, and that points to a genuinely exciting opening for Teva as well as for prospective investors. Shifting to the following slide — something we've covered during the past couple of years — we're now starting to watch a number of these products actually make it to market. Naturally, WELTRUZA has come up in our discussions. We've also discussed what each of the pipeline assets could contribute near term in Q1. At this point we've brought BXCL501 into the picture; we have a pipeline here that we believe can bring in more than $10 billion in sales for Teva down the road. We'll share additional specifics at our R&D day coming up next week. Moving along now to the generics business. One thing that's exciting is that we'll have a generic powerhouse that's resilient even beyond generic REVLIMID. Let me walk you through the fundamentals behind that. Excluding generic REVLIMID, our global generics business grew 1% — the U.S. was down 3%, the EU was up 7%, and emerging markets were down 4%. For 2026, we're expecting our generics business to be flat to slightly up, but we remain positive on this business's long-term growth trajectory of 1%-2% over the long term. I'm still very optimistic about what lies ahead for our generics business, and a key reason for that confidence is that the growth rate really centers on our rapidly expanding biosimilar portfolio pipeline. Moving to this next slide, you can see it plainly here. This is among the biosimilar operations expanding most rapidly in our portfolio. Our original target was $800 million in sales by 2027. Today, I can tell you we'll reach that goal in 2026 — one year early. Alongside that, the portfolio is growing from nine assets in 2024 to 15 as of now, with 18 possible by 2027. Still, keep in mind this isn't merely a matter of adding assets. We're intentionally steering the mix toward biosimilars, which are an ever more significant growth engine for our generics business. Crucially, execution matters just as much as what's in the portfolio. As you can see, in the U.S. we rank first in three of the five. In biosimilars, we hold the top spot, and across Europe we're establishing leading positions in a number of key markets. Moving to the following slide, our work continues along this path, broadening the portfolio and delivering these biosimilars into markets in the U.S. and Europe alike. As you can see on this slide, we have the potential to be — well, we already have 31, though I've noticed this slide is now outdated given the deal with Samsung that we announced today, so the figure ought to be 32. My apologies for that, but it genuinely shows how quickly we operate at Teva. With this strong base of innovation and the shift of our generics business toward biosimilars, let me go to the next slide and state that we remain firmly on track to hit the 2027 targets we set out back in 2023; with that, I'll pass things over to Eric.

Eric Hughes executive
#4

Thank you, Richard. On my first slide, I'd like to walk through quite briefly how our innovative growth drivers have been advancing. A trio of neuroscience products leads this effort, starting with the approval of WELTRUZA, then the hoped-for approval of ecopipam for Tourette syndrome in 2027, and lastly our new drug dexmedetomidine, which is being used to treat agitation. We're expecting a PDUFA date in Q4 of this year. So it's really a strong spearhead, with our neuroscience portfolio out in front. Next comes our expanding innovative pipeline in immunology, starting with DARI, which will wrap up our phase III study soon, with our last castration hopefully near the end of this year. We're also moving duvakitug forward; it's clearly in phase III now, and also in colitis and Crohn's disease. In addition, we'll be launching studies in hidradenitis suppurativa and subclinical Crohn's disease together with our partner Sanofi. And then there's our anti-IL-15 program, where we generated exciting new data this year from our proof of concept study in vitiligo and celiac disease. So this is a genuine engine of growth for our innovative drivers. On the next slide, though, the real belle of the ball today is WELTRUZA. It's a fantastic product for patients with schizophrenia, building on the well-known efficacy of olanzapine, but we truly delivered on the label with no loading dose, no oral supplementation, and no post-injection monitoring. I have to give a shout-out to the R&D team for doing such a great job developing it, and I appreciate that the FDA received our dataset so well, granting a label that really gives patients something they can use in the future. So kudos to the team; on the next slide, I just want to go over the fact that there's been a lot of momentum since the last earnings call in Q2. Since then, we announced the priority review for ecopipam. We submitted the IND for the hidradenitis suppurativa study of duvakitug. We announced and shared top-line data showing clinically significant changes in our gluten challenge for celiac disease. We presented our vitiligo data at the EADV conference in September. We reached the futility analysis for emrusolmin. Unfortunately, that didn't turn out the way we wanted, but the team did a great job executing the study, and we'll review the loads of data we've produced to see how we'll bring that program forward in the future. But really, WELTRUZA was a big announcement on October 8th. Finally, we presented at UEG Week the duvakitug maintenance data, which brought the entire year full circle, presenting that great data for duvakitug. So there's lots of momentum just in the last quarter, and we're very proud of that work. If I go to the next slide, you can see we're marching down the catalysts that we outlined at the very beginning of the year. Duvakitug, ecopipam, anti-IL-15, DARI, emrusolmin — and now WELTRUZA joins the list, while PD-1/IL-2 and dexmedetomidine will come up at the future R&D meeting next week. Last thing from me: I intended to keep this brief today, since we'll have far more to say about deep dives across our pipeline, plus some new programs and fresh data, which we'll present next week on November 11th at our R&D day. I'd encourage people to call in and listen to the webcast. For further details, simply head to our website or send us a note; with that, I'll hand things over to Eli Kalif.

Eli Kalif executive
#5

Thanks, Eric, and hello everyone, morning or afternoon depending on where you are. I want to open my review of the Q3 2026 results with a few central messages. First, keeping our innovative growth momentum going: we anticipate continued strong product mix outcomes, backed by disciplined commercial execution and targeted investment as we shift toward a high-margin profile. Second, we will stay on a credible path toward a 30% operating margin by 2027. That means capturing the full benefit of the transformation program — structural cost savings, productivity gains, and operating leverage from a more favorable growth and product mix — while actively offsetting erosion in generic revenue and earnings. Finally, we will carry out a disciplined capital allocation strategy. We’ll keep our balance sheet flexible, put debt paydown first, and stay disciplined about executing our financial policy. That gives us an investment-grade profile, lets us pursue targeted business development investment while speeding up innovative R&D, and keeps us focused on shareholder return. Now I’ll begin with our Q3 GAAP performance on slide 30. Before I get into the Q3 results, let me take a moment to explain why we also reflected the IPR&D impact. IPR&D can create substantial upfront and milestone expenses tied to investments in pipeline assets that we acquire or license from outside parties. Because these expenses depend on transactions, beginning with Q3 2026 we are presenting how those transactions affect our results, so you get a clearer and more comparable picture of our underlying operating cost performance. Third-quarter revenue came in at roughly $4.4 billion, a 2% decline versus Q3 2025 both in U.S. dollars and on a local currency basis. The drop stemmed mostly from weaker generics products, primarily generic REVLIMID revenues, and was largely offset by sustained strong growth across our key innovative products, AUSTEDO, AJOVY, and UZEDY. GAAP net profit and profit per share came to $233 million and $0.20, respectively. Now moving to our non-GAAP results. Non-GAAP gross margin for Q3 2026 reached 58.7%, up 245 basis points, which reflects a favorable product mix with strong growth in our key innovative products, partly offset by low revenue from generics products, mainly generic REVLIMID revenue. On a GAAP basis, our operating margin came in at 31.7%, which is 282 basis points better than what we posted in Q3 of last year. The main driver behind that margin improvement was a stronger gross margin, though it was partly offset by planned increases in sales and marketing spend—investments that support our innovative growth and the launch preparation for WELTRUZA—and also by capital gains from a property sale in Europe. All told, we closed the quarter with non-GAAP EPS of $0.86, up 10% versus Q3 2025. Free cash flow for Q3 landed at $495 million, in line with what we expected and a bit under last year's figure. During October 2026, we paid back roughly $1.8 billion of our debt maturity. As of today, nothing is outstanding under our revolving credit facility. To give you a bit more detail, during the first nine months of 2025 our results included roughly $1 billion in revenue and $730 million of EBITDA contribution coming from generics revenue. For Q3 2025 specifically, generics revenue contributed $430 million in revenue and $300 million in EBITDA. If you exclude those, both our year-to-date and quarterly results demonstrate strong underlying performance. Turning to the next slide. As a reminder, there are two structural factors that drive the expansion of our operating margin to 30%. The first is the shift in our portfolio toward innovative products, which offer higher growth and higher margins. The second is the Teva transformation programs. We continue to see steady gains in our everyday operating margin, which comes to 28% under our revised 2026 guidance range of 27.8%-28.2%, in each case excluding IPR&D expenses. As we look toward 2027, we anticipate an additional 180 basis points-220 basis points of improvement, fueled by the full anticipated effect of our transformation program and ongoing innovative growth while offsetting erosion in generics revenue. That is the heart of our financial transformation: shifting from a business entirely centered on generics into a biopharma company. Turning to slide 32. Disciplined financial management has served as a key source of cash generation for us, and importantly, it has enabled us to steer capital toward opportunities with higher returns. Between 2022 and 2026, gains in net working capital produced roughly $1.3 billion in extra cash, plus about $160 million more from reduced interest costs. Combined, that adds up to around $1.5 billion in cash generation we've been able to put back into the business, including speeding up our innovative pipeline and funding our broader priorities. Going forward, we see a chance to keep that momentum. From 2027 through 2030, we anticipate generating another approximately $500 million-$900 million from net working capital, along with approximately $1.4 billion-$1.6 billion in interest expense savings, which brings the cumulative opportunity to approximately $3.4 billion-$4 billion. By the close of 2030, we expect to hit negative net working capital as a percentage of revenue. What matters here is that the more the business expands, the more leverage this gives us. Capital is being released and put back to work where returns are greater, even as we keep expanding and building additional room to invest. Meanwhile, we stay committed to keeping the balance sheet sound; roughly $12 billion in debt has been paid down since 2019, and we are clearly on track to reach net debt to EBITDA of 2x by the close of 2027. Looking ahead, we expect roughly $2.7 billion in free cash flow for 2027. Annual maturities between 2028 and 2030 come to under $1 billion, and for 2030 we anticipate about $2.5 billion in free cash flow. Given that, we see substantial financial flexibility — enough to keep funding our growth while holding leverage at appropriate levels. It really is a self-reinforcing cycle: disciplined financial management produces cash, that cash gets redeployed into a high-return growth opportunity, and as the business expands, our capacity to invest grows even further. Let's now move to slide 33 and the 2026 outlook. Given how well we've done so far this year and what we can see for the rest of it, we're lifting our revenue guidance for the full year to a range of $16.7 billion to $17 billion — that's $175 million more at the midpoint. We're also updating our outlook ranges for operating profit, adjusted EBITDA, EPS, and free cash flow. As Richard mentioned earlier, the BXCL501 acquisition from BioXcel has closed. Here's a quick recap of the terms: the agreement includes a $57.5 million upfront payment, along with up to $67.5 million in contingent payments that depend on the timing of the expected FDA approval and on certain sales milestones. Let me walk through some of the assumptions underlying our guidance, starting with revenue. To start, our innovative portfolio continues to deliver strong results across all three products — AUSTEDO, AJOVY, and UZEDY — and we are lifting full-year guidance for each of them: AUSTEDO is now projected at $2.55 billion-$2.65 billion, AJOVY at $930 million-$960 million, and UZEDY at $290 million-$310 million. For the full year, global generics revenue is expected to be flat to slightly up in local currency compared with 2025, excluding the impact of generics revenue and the divested Japan business. We still anticipate 2026 non-GAAP gross margin of 54.5%-55.5%. Our 2026 operating income expectation is now $3.8 billion-$3.9 billion, reflecting an operating margin of 22.6%-23.1%. Excluding IPR&D, that range comes to 27.8%-28.2%.

Eli Kalif executive
#6

Operating expenses still show the deliberate investments we're making to back our expanding innovative portfolio and biosimilars. Our guidance for operating income and adjusted EBITDA reflects that ongoing growth investment in OpEx, and adjusted EBITDA is now anticipated to land between $4.23 billion and $4.43 billion. If you exclude IPR&D, that range comes in at $5.1 billion to $5.3 billion. We still expect finance expenses of roughly $800 million and a tax rate of 20% to 23%. Diluted EPS guidance now sits at $1.92 to $2.11, and we're also raising our free cash flow guidance for the full year to a range of $2.1 billion to $2.4 billion. Now let me share a few additional thoughts about Q4. For AUSTEDO, we still anticipate revenue in Q4 2026 will decline year-over-year, driven by expected shifts in purchasing patterns and the pricing environment before IRA implementation in January. Beyond that, we're getting ready for the Q4 launch of WELTRUZA. Because initial volume is expected to consist largely of samples or vouchers while we build payer coverage, we still expect no major revenue contribution in Q4. Across the past several years, we've consistently delivered on our commitments and achieved meaningful progress on our key financial metrics. Today we aren't offering a detailed 2027 guidance outlook, but as we look ahead, we expect that momentum to carry forward, with mid-single digit revenue CAGR growth from 2023 to 2027; on slide 69 we laid out more comprehensive information about our financial trajectory. Turning to the next slide on capital allocation. During the last two years, we've made substantial progress strengthening our balance sheet. That progress gives us the financial flexibility to invest in our innovative portfolio and pipeline, to evaluate value-accretive business development opportunities, and to retain the optionality of returning capital to shareholders via buybacks when appropriate. Finally, I'd like to briefly mention our move to a direct ordinary share listing on the New York Stock Exchange. We believe this change makes Teva shares more accessible to a broader investor base, who can now purchase ordinary shares directly in a seamless way, and it strengthens our position in the U.S. capital market. Along with our recent return to an investment-grade credit rating from all three major rating agencies, this marks another important milestone in our financial transformation. We believe this transition reflects the momentum we're building through our pivot to growth strategy and further enhances our ability to invest for long-term growth and create shareholder value. With that, I'll now hand it back to Richard for his closing remarks.

Richard Francis executive
#7

Thanks, Eli. To sum up, Teva today stands as a biopharma company that is more focused and higher-growth, and the strategy of pivoting toward growth is paying off. The innovative portfolio's growth engine is picking up speed. AUSTEDO, UZEDY, and AJOVY serve as growth drivers, and the recent FDA approval of WELTRUZA has us excited; going forward, incremental growth will come from the next generation of innovation. To wrap up on the next slide, as our journey continues, three themes stand out; in what was a pivotal year for Teva, we delivered as promised. Our pipeline is moving forward with speed. Disciplined capital allocation is the thing that sets us apart. Building on what Eric said, we look forward to seeing you at our R&D day next week in New York City. With that, I'll open the floor to questions.

Christopher Stevo executive
#8

Apologies, Eli, before you line up the queue, I wanted to remind everyone to please keep it to one question plus one follow-up. Should you have more questions, feel free to rejoin the queue, and we will get to as many as time allows. Sorry, please continue, Eli.

Yoon Choi executive
#9

Hi everyone — apologies, and thanks for taking my question. Omar here. I wanted to bring up two items. First, on that final slide there's a notable disclosure regarding a potential 57%–58% gross margin in 2027. I believe that's the first time it's been shared, and it represents a pretty healthy step up from the approximately 55% gross margin expected for the full year 2026. So my question is this: assuming AUSTEDO stays roughly flat next year owing to IRA implementation, what would you point to as the drivers behind those 200 to 300 basis points of gross margin expansion, which presumably don't come from the branded business? Second, on AUSTEDO specifically, I'd like to walk through some numbers with you. To start, Gilead noted roughly $1.5 billion of IRA effect on BIKTARVY — that's somewhere from 25% to 33% of its Medicare exposure. Given AUSTEDO's Medicare exposure sits at approximately $1.5 billion, would it be fair to estimate around $0.5 billion of IRA exposure for AUSTEDO going into next year? Thank you.

Richard Francis executive
#10

Thanks, Omar, and thanks for the question. I appreciate that you went through every slide, including the ones in the appendix, so thank you for doing that. I will pass things to Eli so he can discuss the gross margin a little. Still, one point I would make at a high level is that when we disclosed the direction of travel for our gross margin at our capital market day, what you are seeing, I think, is that the shift into a biopharma company is speeding that up, since our portfolio is moving at speed and at scale, together with some of our efficiency efforts. But I will turn it over to Eli for a bit more context and detail.

Eli Kalif executive
#11

Thanks, Omar, for that question. We did say previously that with 57%-58%, while maintaining the 27%-28% OpEx, we'd get to the 30% OP, but that's really just the high-level picture. What I'll point out is this. Looking at just this quarter, we're actually going to come in above 58%. Compared with last year, the same quarter was slightly above 55%. That's roughly 350 basis points, driven mostly by the innovative shift in our revenue mix. To remind everyone what we'll see next year, we have the $700 million in transformation savings. About two-thirds of that is actually tied to OpEx, and we're going to actually use it and recognize it this year. The remainder of the problem is more of a backlog tied to our network optimization, which will impact our cost. If you think about us finishing the year close to, I'd say, the high range of 55.5%, you take 200 basis points to the midpoint. That's 67%-68%, with roughly 100 basis points going to manufacturing and optimization of our COGS, and 100 basis points going to our innovative revenue shift.

Richard Francis executive
#12

Thanks, Eli. Look, one thing I would mention regarding that upward path for gross margin is that it will simply keep going. The only uncertainty is the size of the increase, yet it will carry on thanks to the reshaping of our portfolio and the reshaping of the launches we have lined up. On your second question, Omar, from a technical standpoint, yes, you are correct; that is likely the first point to make. Without discussing guidance, in line with how we have done things before, we will give guidance in 2027, next year. Yes, we hold a high level of confidence that AUSTEDO will reach $2.5 billion next year and more than $3 billion at peak. 2027 was a year we always planned for. Strong fundamentals are offsetting the IRA impact, and that is what gives us that confidence. I would say, just to offer even broader context, what has really shifted is that the company now has a portfolio of drivers feeding into AUSTEDO. Again, without providing guidance for 2027, we expect Teva's revenues to grow once more. Beyond UZEDY, AJOVY, Renav, and WELTRUZA, plus ecopipam, and then possibly the BXCL501. Our innovation portfolio lets us keep growing past 2027, in 2027 and beyond, and that lets us grow our margins. I think that is a good question. I appreciate you asking, since it has multiple layers, but it ultimately comes back to how well we execute the pivot to growth strategy, how well we execute the move to a biopharma company with a rapidly expanding innovative portfolio. Thanks for the question, Omar.

Douglas Tsao analyst
#13

Morning — appreciate you taking my questions. I've got two, covering AUSTEDO and AJOVY. Starting with AUSTEDO: I see milligrams per patient continuing to climb, which makes me curious. Part of that clearly reflects the natural shift over to XR, but looking just within XR, how much further traction are you still gaining? I understand patients by and large aren't getting to the 36.6 mg per day seen in the phase III trial — so how big a priority is it to eventually bring patients up to that level? I've got a question about AJOVY, since that franchise has been growing strongly again lately. I'm wondering what you're seeing in the U.S. when you look at the outlook. From a revenue-per-patient angle, it seems you're performing better, and how do you expect share to play out? Over the longer term you've clearly been taking share from Aimovig, and how much of the growth will come from the U.S. compared with ex-U.S.? Thank you.

Richard Francis executive
#14

All right. First of all, thank you — I think that's the right word for the coverage, so I appreciate it. Thanks for your questions. Let me try to address them. I'll begin with AUSTEDO. You mentioned the milligram growth there, 22% in Q3. I'll walk you through how that came about—there are a few factors involved. The first was the introduction of XR, and alongside it came the option to obtain a titration pack by prescription. With AUSTEDO, patients must titrate upward until they reach the optimal dose that delivers efficacy. So when a titration pack can be prescribed and XR is taken just once daily, the whole process becomes easier—that's the real driver behind the shift. We haven't made any active push to convert patients from BID to XR; that decision has been left to the physician. So, with those two elements now in place, we've observed steady gains — which benefits patients, since our goal is to keep them at the dose that works best. One challenge and opportunity with AUSTEDO is that patients tend to feel the effect fairly fast, yet we want to ensure they ultimately land on the regimen that's optimal for them. That responsibility falls to the physician, who can leverage the titration pack and XR to get there. So that's the core of it, and we expect that progression to continue this year and beyond. Turning now to your question about AJOVY — AJOVY, I believe, was roughly in the U.S. Turning to how things are performing—how solid that is—and then how the rest of the world is doing. Let me walk you through the U.S. first. U.S. performance ties back to something I mentioned in my opening remarks: it comes down to focused execution in delivering a strategy at the brand level. What ought our global strategy to be, what should stay local, which capabilities do we need to build around that, which resources, and which decisions have to be made? In the U.S., I believe we've watched the team's work there and made calls to make sure we have the right access and the right value. And when you do that, along with growing market share, you then have the ability to

Richard Francis executive
#15

Now, as for the rest of the world, there's an opportunity here, and as you've observed, in Europe and international markets we keep expanding faster than the market — considerably faster than the market — and that's why our market share is growing. So in order to achieve that, revenue growth is something we keep seeing. I think what this brings into focus — and I realize this is an unusual situation — is that with focus, capability, and the right resources, along with the right ambition and expectations, a brand can be revitalized. And I think AJOVY has shown us that; so that's the reason we stay confident it will exceed $1 billion in peak sales, which obviously sounds like a big number, particularly when we began our conversations nearly four years ago. Hope that answers your questions. Thanks very much.

Glen Santangelo analyst
#16

Oh, right. Appreciate you fielding my questions. Richard, I just wanted to briefly cover a couple of items. On that slide about the biosimilar launch, you noted how much more crowded the space is becoming, but I'm sure you're aware there's been quite a bit of additional litigation in this area. To give examples, Janssen is seeking a PI on SIMPONI, Genentech has filed a suit concerning XOLAIR, and there's substantial worry regarding ENTYVIO and when it launches, in light of the IP circumstances at Takeda. I'm just wondering how Teva approaches all that possible litigation and decides whether to move ahead with launching these products, since that slide seems to show some incremental contribution from these drugs arriving in 2027; and then second, I wanted to ask about 2027 with respect to ecopipam and BXCL501. I'm sure you'll cover this at the R&D day next week, but at a high level I'm just curious: do you anticipate any kind of reasonable contribution from those two drugs during the second half of 2027? Thanks, and I'll leave it there.

Richard Francis executive
#17

Hi, Glen. Thanks for the questions. Regarding the biosimilars litigation question — yes, that's essentially the nature of our business in generics and biosimilars. Our goal is to launch these products, and others aim to sue to block us. So it doesn't really catch us off guard. Naturally, we'd prefer things weren't that way, but our strategic and financial planning is realistic. When we look at our portfolio of 32 now, we factor in the gains and losses. At the outset of this effort, whenever people asked me which biosimilar would end up being the biggest winner, my answer was that I had no idea—there are simply too many moving parts, including IP, litigation, launch timing, how many competitors show up, price erosion, and so forth. Having a portfolio, though, lets you handle those risks more intelligently, and that in turn lets you keep growing. That's why I have a lot of confidence in where our biosimilar business is headed. What matters to recognize at this point is that we're building real momentum and scale, and that is set to reshape our generics business portfolio in a fundamental way. I think folks should perhaps dig into that point and recognize it. That's one thing. Another point I'd make about the biosimilar business is that, to some degree, it doesn't follow all the traditional rules. As I said, three out of five of our biosimilars in the U.S. are number one; we were not number one to the market. That just shows you it's not as straightforward as people think, and I like that. The same in Europe. In many cases we've arrived in Europe on the late side, yet we're also demonstrating that we can become number one in those markets thanks to the capability and infrastructure we already have in place. About biosimilars, you'll be hearing more from us on that front, but our plan is to keep expanding that portfolio. Litigation is going to come up, and we'll deal with it whenever it happens, but it won't throw us off track. Now, on ecopipam and BXCL501 — look, Glenn, I need to make sure you're there next week, so there's nothing I can share with you. The one thing I'll say is that it's a good question, and it's the right question, and we'll start giving you some insight into why these two products excite us. As for whether we'll give any guidance on that, you'll just have to wait and see. Still, it's good that those are starting to get your attention, since I think we've shown that in our hands they can genuinely create value. We were just talking about AJOVY, but if you look at ecopipam and the major unmet need it addresses, and at BXCL501 and the major unmet need in agitation, we're quite enthusiastic about what we might accomplish with them. Sorry—I'll be seeing you in New York next week.

Glen Santangelo analyst
#18

No problem. Thank you. See you next week.

David Amsellem analyst
#19

Thank you. I've got a few ecopipam questions, actually, with more of a longer-term focus. In your slide you didn't give peak sales potential for the product, which is different from other pipeline products or ones recently approved. So maybe just a question about how you're thinking qualitatively on how impactful this product might be. How are you approaching access dynamics, the Medicaid versus commercial mix, and how long do you think good access will take to achieve? Are there any pricing analogs you can give us to help frame that? And then, do you think this product could slot in ahead of the approved antipsychotics that are commonly used? I know that's a lot, but it's clearly an important driver going forward. Thanks.

Richard Francis executive
#20

Thanks, David. Thanks for the question. No, it's a really good one, and I'll give Eric a heads-up that we'll discuss that third line moving ahead of antipsychotics. I think you've touched on all the variables we're thinking about there. First off, there's the fact that we have to think about what the appropriate price is for such an innovative product that's going to bring compelling efficacy along with good tolerability and safety; we're doing a lot of work on that right now, because obviously that's a very important factor in this equation. That's another reason we don't want to start talking about sales and peak sales, because we want to get that work done, and we want to make sure it's as thorough as it can be. As we've said before, the pricing will reflect something of a rare orphan nature, where there's a significant unmet need in the pediatric population. The second thing that comes down to then is access, and how do we want to approach access? As you know, we're very thoughtful about access, and we think about the long-term value of a product and how you have to be thoughtful in what you do with regard to access around that. We're working through that. With regard to Medicaid and commercial, the mix is a bit different here. I think we're looking at more commercial plans on this product, which, as I stated before, is a change for us because we've spent a lot of our time dealing in Medicaid and Medicare. I think that's how I would think about it; but I'll hand over to Eric, but what I would say is, when I get to speak to physicians and when I actually get to speak to patients, and I've actually even come across some people who suffer from Tourette syndrome, then there's a clear opportunity for an efficacious and safe and well-tolerated product to move ahead of an antipsychotic. Though perhaps I'll pass that along to the doctor who's here with us.

Eric Hughes executive
#21

Thank you, Richard. So I believe what makes ecopipam valuable really boils down to the data sets we've produced so far. We now have two well-controlled trials, one in phase II and one in phase III. One showed a 30% reduction in the tic experience for patients along with a 50% reduction in the relapse rate; that's great data, but even more importantly, the side effect profile was favorable, I think, with very good tolerability, no metabolic effects, good activity against their tics, and no abnormal movement disorders. So when I consider how physicians may use this going forward, sure, they might first step through what they do today with alpha-adrenergic receptor agonists, which is off-label, and then they might move on to an antipsychotic. But I think once they get used to what ecopipam's profile is and develop an understanding of both the efficacy and the safety profile, it will rise higher on that list of possibilities out there. I think with long-term efficacy, remember, only about mid-20s do people stay on their therapies today. In our long-term follow-up, 66% of patients remain on the drug for perhaps a year. So I think the profile, once physicians get used to it, will move up in that armamentarium.

Richard Francis executive
#22

Thanks, Eric. Thanks for that answer, and thanks for the question, David.

Jason Gerberry analyst
#23

Good morning, and thanks for taking my questions. First one is for Eric: what's the timeline looking like for Teva's work to move a TL1A bispecific into the clinic? I know you've had some efforts going on pre-clinically, so is there anything you can update us on regarding that timeline? Then my follow-up: does the U.S. government agreement keep Teva out of some of those generic tariff headline proposals, or I'm not sure exactly what to call it, but does that agreement give exemption from any generic tariff risk? Thanks.

Eric Hughes executive
#24

I can begin, and answer the TL1A bispecific question. I'll disappoint you straight away. I won't be telling you much, because we have an R&D day next week, and we may be discussing bispecific programs with our TL1A. I would note that we are among the first in the TL1A space. We have a very potent, highly selective drug with low anti-drug antibodies in full phase III. I think our scientists are the experts on TL1A, and next week we'll hear more about that.

Richard Francis executive
#25

On your question, Jason, about generics and any deal with the U.S. government, as they set out, I believe a while back, they've established a two-year timeframe for reaching some kind of agreement. Nothing has been finalized on that front. As you'd expect, a company such as Teva is always engaged at the table. Whenever we learn more, we'll let you know.

Louise Chen analyst
#26

Hello, and thank you for taking my questions. Congratulations on the quarter as well. First, I'd like to hear your most recent thoughts regarding M&A and business development. Second, could you expand a bit more on your R&D philosophy and on how efficiently you advance products through the pipeline? Thanks.

Richard Francis executive
#27

Hi, Louise, and thanks for asking. On M&A, what we focus on is deploying capital efficiently at all times. Clearly, that's something we think about a great deal, and we've thought about it a great deal over the last few years, even though people believed today would never arrive. By today, I mean a balance sheet that keeps improving, investment grade, and, as Eli mentioned, a chance for the company to genuinely generate free cash. So obviously, we know our balance sheet will begin to improve significantly. Because of that, we were planning for this day all along. I hope there are things people will start to recognize. We do plan for Teva over the long term. For Teva, we begin to consider what might be around the corner; so yes, we do consider additional business development deals. We consider potential M&A, but it must be a deal that we believe offers good value, drives the company's long-term value, and puts us on a sustainable footing to become a world-class biopharma company. I think hopefully the deals we've done show that we're very thoughtful about how we deploy capital externally and about making sure we do things that we know will drive good accretion in the short term as well as the long term. So that's our philosophy. The balance sheet gives us somewhat more flexibility, but our discipline will not change. Now, on the R&D philosophy. Are you going to tell them anything?

Eric Hughes executive
#28

I might give them a headline. How is that?

Richard Francis executive
#29

Okay, let's give them the headline.

Eric Hughes executive
#30

Yes, thank you for asking, Louise. My view is that the strategy and philosophy are quite straightforward. We'll discuss this further next week, but essentially it involves applying established science to boost your POS, speed and execution on the ground rather than through AI, along with disciplined capital and leveraging partnerships wherever you can expand your bandwidth and your funding. It's truly simple, but execution is what matters.

Richard Francis executive
#31

Thanks, Eric. Thanks, Louise. Thank you for the question. Next question.

Dennis Ding analyst
#32

Hey, guys. Good morning. I have two questions, if that's alright. First one is on WELTRUZA. You described the market as 2 million diagnosed in the U.S. and 20% on oral olanzapine, so basically you're implying a TAM of roughly 400,000. But how does that TAM shift considering lots of patients can't tolerate olanzapine due to weight gain and eventually stop taking it? WELTRUZA probably will carry a similar side effect profile, so where do you realistically see WELTRUZA being used? In a way, I suppose I'm asking whether you have an estimate of how many patients have demonstrated efficacy on olanzapine, can handle the weight gain, but also show signs of non-compliance; that's my first question. Second question, on biosimilars, could you clarify once more and confirm on slide 20 that you plan to launch a SIMPONI biosimilar in the U.S. in 2027? I'm just curious because how are you factoring in the litigation side here as an obstacle to a U.S. launch? We ask because the four-day bench trial J&J has against Bio-Thera begins March 2028, and I'd assume your partner's bench trial would be set around that same period. Just help me square the timing differences here, and whether what you're suggesting is that you'll be aggressive about pursuing a settlement to secure a 2027 U.S. SIMPONI biosimilar launch. Thanks so much.

Richard Francis executive
#33

Okay. Thanks, Dennis. Thanks for the question. I'll take the first one together with Eric. The way we look at it, the reason olanzapine holds such a large share of the schizophrenia market is that it's highly efficacious, and it's regarded as the gold standard on efficacy. While you've pointed out some of its metabolic challenges, when it comes to managing schizophrenia, when patients have severe schizophrenia, efficacy is the top priority. That's why olanzapine has kept that segment of the market. Obviously, with severe schizophrenia, compliance becomes critical, and that's where we believe WELTRUZA fits in. In a sense, we aren't dealing with those side effects. They're already known, and people choose olanzapine for the efficacy, both the physician and the patient. But I'll let Eric add more context on that.

Eric Hughes executive
#34

Sure, let me give you a bit more detail on WELTRUZA. What makes it valuable is that its efficacy is well established and so is its safety profile. So a physician is already using something, but now you're adding something new through the LAI. Roughly 20% of the market is already using olanzapine. That shows how widely known it is and how accustomed they are to using it. So delivering that convenience, along with the hoped-for benefit of fewer relapses and better adherence through an LAI, is really the value proposition here. I think that makes it very easy for a physician to decide which patients should receive it. And I would add that we've done the same thing with UZEDY in the crowded risperidone space here. We're launching into an LAI market that truly has no viable alternative at this point.

Richard Francis executive
#35

Thanks, Eric. Now, regarding your question about the biosimilar SIMPONI: when we discuss launch readiness, we mean having the capability to launch. Whether we actually do so can vary, since that hinges on several factors—but we always position ourselves so that we could launch if the opportunity arises. That's how you should view it. Clearly, IP litigation can unfold in many ways, yet what I consistently stress is that we must be prepared; then, should events proceed as we intend or as we hope, we will be ready to ensure patients can get access.

Dan Clark analyst
#36

Good morning, everyone, and thanks so much. My first question concerns the AUSTEDO slide. You mentioned that new capabilities have been put in place to help with MFP effectuation next year. Could you shed some light on what those capabilities involve and how they could influence either sales or price next year? My second question is about getting a clearer picture of how you're viewing the timing of WELTRUZA revenue next year. Should we be thinking of it as landing more around mid-year while you work on securing access, or any insight you can offer there would be very helpful. Thank you.

Richard Francis executive
#37

Thanks, Dan, and thanks for asking. Beginning with WELTRUZA in reverse order — the revenue we expect from it lands in the back half of the year. Let me walk through the reasoning a little. The launch happened during this quarter, and the whole point is to build access and familiarity with the product, both on hospital formularies and among physicians. As you probably know, most of our patients are in Medicaid and Medicare. Gaining access to WELTRUZA means securing it on Medicaid formularies. Each plan limits that, so certain plans will do it at launch while others take six months, nine months, or 12 months. Once we reach 12 months, roughly 85% of Medicaid coverage will be in place. One major constraint is access. Beyond Medicare, Medicaid is the real issue. On the input side, we do things like sampling and working with hospital formularies to ensure the product is listed on them, but in the end, access is what matters most. That means you won't see meaningful revenue during the first half of next year. Once many of those states come on board, physicians will have the chance to use WELTRUZA more widely. That's why we point to the second half of next year. Clearly, having a complete year in 2028 shifts that picture considerably—that's the way I'd frame it. Our commitment is to keep everyone current on what I refer to as the inputs, or leading indicators, tied to TRX, to access, to how broadly physicians prescribe, and to how deeply they use it. Given the product profile Eric described, the unmet medical need, and the truly robust capability we've established with UZEDY, our confidence in where WELTRUZA is headed runs high. Regarding AUSTEDO, I believe the question concerned the capabilities we've developed to reduce the fallout from the IRA and its taking effect. Honestly, this is largely a continuation of what we've already been doing, since this has been on our radar for quite a while. We aren't about to enter 2027 without having done our homework. As we've mentioned, we've spent several years getting ready for the shift toward growth that 2027 brings; we saw it on the horizon. From 2023 through 2027, we anticipated this development. We've invested effort in building out our capabilities and refining our approach so we're ready for it. I'd say we're well positioned, and that reflects many factors: how we serve patients, how we run specialty pharmacy, how we manage access, and how we support patients through the different points along their journey. Those pieces were set up a while back. That's part of why we feel confident about continuing to grow this product past $3 billion eventually. 2027 is really just one point along the way there. As I've said, we always plan for 2027. The challenge in front of us doesn't intimidate us in the slightest.

Joseph Thome analyst
#38

Hello. Good morning, and thanks for taking my questions. Perhaps one on the commercial side first. Just as you're seeing with the LAIs, obviously one of the benefits can be time on therapy and better compliance. What are you observing when it comes to real-world UZEDY refill rates and how long patients stay on therapy? Has that been in line with your expectations before launch? Then maybe one about the pipeline. We've seen several celiac datasets this year. How is Teva weighing speed to market against competition, and also getting full alignment with the FDA on which endpoints they want and clinical trial success? Thank you.

Richard Francis executive
#39

Thanks for the question, Joe. Regarding compliance and adherence, I can't give you any kind of specifics for WELTRUZA, but what we observe with the other long-acting product on the market is that there is greater, as you'd expect, compliance and adherence. You move from having a daily pill or multiple pills to an injection once a month, or for UZEDY, once every two months, and obviously compliance and adherence rise quite substantially. We believe that is a benefit, obviously, for the patient and for realizing that efficacy, but obviously for staying on therapy. By the way, compliance and adherence, I'm sure you're aware, really matters in schizophrenia because each relapse actually harms the brain. The effectiveness of the medication afterward begins to decline somewhat. You want to avoid any of that. So compliance and adherence are essential, which is why when you have a product such as UZEDY that is simple to use, simple to administer, no loading dose, reaches blood levels within 24 hours, it gets used substantially because they want our patients to comply. And we see that same opportunity for WELTRUZA. I don't have any details there. Maybe we will look into that and see whether we can find some datasets. But it appears very clear from what we've seen with UZEDY. But thank you for that question. Now, moving on to celiac in the pipeline. I will hand that one to Eric to speak a bit about that and our approach to it.

Eric Hughes executive
#40

Yeah, and thank you for asking about celiac disease, plus the wider topic of the FDA, endpoints, and how fast we can reach the market. Every avenue that could shorten timelines is something our teams make use of. The biosimilar area has shifted a great deal, and we were involved in those discussions from very early on, and we have also taken part in talks about accelerating standard phase III programs in which you run one pivotal trial rather than two. Depending on what the science indicates, we examine each possibility every time; in celiac disease, we are progressing at a very rapid pace there with the data we have recently produced in our proof of concept study. That is shaping our discussion about how our phase IIs and phase IIIs should be designed, and next week we will share a bit more on that. Still, we have definitely zeroed in on what we believe those celiac design studies will look like. Meanwhile, we are advancing very rapidly into anti-IL-15, which offers a very clear endpoint and a pathway to registration. But thank you for the question.

Christopher Stevo executive
#41

Elliot, sorry about that. I have to apologize. There's only time for one more question, but as we talked about earlier, we can follow up with the sell-side analysts afterward. So please stay tuned, and any additional questions we can take after the call. So let's have our last question, please, Elliot.

Chris Schott analyst
#42

Thank you, and I appreciate the question. I might break it into a couple of pieces, regarding how we're viewing investment going forward. So as we consider R&D programs like TSLP IL-13, or any other wider immunology-type programs you might think about, would you seek to partner on those in the same manner you did with the TL1A, or do you believe these are assets Teva is now able to advance independently, given the larger footprint, the investment opportunity, and so on, that you have on the branded side? And perhaps a second piece to that. I know you brought up a futility with emrusolmin. Would you make a similar wager on another high-risk, high-reward asset, or has the BID shift also gravitated toward assets with less risk given how the company has changed? Many thanks.

Richard Francis executive
#43

Thanks, Chris, and thanks for asking. Regarding that example — TSLP IL-13 — the way we frame it, and you'll hear more on this next week at the R&D day, is fairly straightforward. When we discover science that works, we'll pursue it hard and fast, and we'll figure out the funding along the way, as it were. What that means, though, is that we remain mindful of our pledge to grow shareholder value and to respect margins. That said, Teva's starting position on gross margin gives us greater room to maneuver than most companies have. That's the lens we use. As for whether we need a financial partner for TSLP IL-13, time will tell. We'll find out how many indications it can reach, and how many parties want involvement — whether through financing or through other companies. I think that illustrates the optionality Teva holds for handling products with multiple indications in exciting areas. So that's the first point. On the second part, which is on — I've lost it now.

Eric Hughes executive
#44

A genuine success with MR.

Richard Francis executive
#45

Oh, yes. So does that mean we won't pursue those assets with perhaps a low probability of success down the road? Yeah, I guess that's the straightforward response; and then you'd likely ask, "So why did you take on this one?" Well, when Eric and I joined forces back in 2023, we examined it and figured that reaching the stage we're at today actually demanded very little capital; we had a fairly solid grasp of the science and believed it might have a shot; and for that reason, we moved ahead and pursued it. So capital allocation played a major role. We didn't have to There was no opportunity cost attached to this one, if you will. Looking ahead, we don't feel the need to keep doing that. We aim to concentrate on areas with a high likelihood of success. That's our R&D strategy, that's our BID strategy, and that's how we believe we can reliably deliver solid returns to our investors across a long stretch of time, by being genuinely careful about capital allocation and risk. Thanks, Chris. Appreciate your question, and I believe that was the final one. So I'd like to thank everyone for their interest in Teva and their ongoing interest in Teva, and I'm looking forward to seeing many of you in New York at the R&D day next week. Many thanks.

Eric Hughes executive
#46

Thank you, everyone.

Christopher Stevo executive
#47

Thank you, Elliot.

Operator operator
#48

Ladies and gentlemen, that brings us to the end of today's call. Thank you all for joining us. You can go ahead and disconnect your lines now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Teva Pharmaceutical Industries Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Teva Pharmaceutical Industries Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.